Biophytis SA
ALBPS
Company Profile
Business description
Biophytis SA is a France-based biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging and improve functional outcomes for patients suffering from age-related diseases. Its drug candidate BIO101, is an orally administered small molecule in development for the treatment of neuromuscular diseases, including sarcopenia and DMD.
Contact
BC 9, Batiment A 4eme etage
4 pace Jussieu
Sorbonne University
Paris75005
FRAT: +33 144272300
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
24
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,660.30 | 22.50 | 0.26% |
| CAC 40 | 7,751.89 | 27.83 | -0.36% |
| DAX 40 | 23,997.48 | 64.25 | 0.27% |
| Dow JONES (US) | 41,970.95 | 244.78 | -0.58% |
| FTSE 100 | 8,772.38 | 55.93 | 0.64% |
| HKSE | 23,289.77 | 283.61 | -1.20% |
| NASDAQ | 18,864.20 | 311.67 | -1.63% |
| Nikkei 225 | 37,965.10 | 467.88 | -1.22% |
| NZX 50 Index | 12,418.89 | 137.58 | 1.12% |
| S&P 500 | 5,852.18 | 59.99 | -1.01% |
| S&P/ASX 200 | 8,434.70 | 24.90 | 0.30% |
| SSE Composite Index | 3,347.49 | 15.96 | -0.47% |